W. Sugiura

发表

A Multi-Center, Open-Label, Randomized Controlled Trial to Evaluate the Efficacy of Convalescent Plasma Therapy for Coronavirus Disease 2019: A Trial Protocol (COVIPLA-RCT)

M. Satake, Y. Takamatsu, S. Kutsuna, 2022, Life.

Coronavirus Disease 2019 (COVID-19) Breakthrough Infection and Post-Vaccination Neutralizing Antibodies Among Healthcare Workers in a Referral Hospital in Tokyo: A Case-Control Matching Study

N. Ohmagari, J. Takeuchi, H. Sugiyama, 2021, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Association of Impaired Fasting Glucose and Diabetes with SARS-CoV-2 Spike Antibody Titers after the BNT162b2 Vaccine among Health Care Workers in a Tertiary Hospital in Japan

N. Ohmagari, A. Tanaka, T. Mizoue, 2022, Vaccines.

Efficacy and Safety of Direct Hemoperfusion using Polymyxin B-Immobilized Polystyrene Column (PMX-DHP) for COVID-19 Patients: Exploratory Study Protocol.

H. Sugiyama, Y. Uemura, A. Azuma, 2022, JMIR research protocols.

Sensitivity of anti-SARS-CoV-2 nucleocapsid protein antibody for breakthrough infections during the epidemic of the Omicron variants

N. Ohmagari, H. Sugiyama, T. Mizoue, 2022, Journal of Infection.

Neutralising activity and antibody titre in 10 patients with breakthrough infections of the SARS-CoV-2 Omicron variant in Japan

N. Ohmagari, J. Takeuchi, S. Tsuzuki, 2022, Journal of Infection and Chemotherapy.

Comparison of the clinical characteristics and outcomes of Japanese patients with COVID-19 treated in primary, secondary, and tertiary care facilities

Y. Hiroi, S. Kutsuna, N. Ohmagari, 2022, Journal of Infection and Chemotherapy.

Association study of HLA with the kinetics of SARS-CoV-2 spike specific IgG antibody responses to BNT162b2 mRNA vaccine

N. Ohmagari, J. Takeuchi, Y. Omae, 2022, medRxiv.

Neutralizing antibodies after three doses of the BNT162b2 vaccine, breakthrough infection, and symptoms during the Omicron-predominant wave

N. Ohmagari, J. Takeuchi, H. Sugiyama, 2022, International Journal of Infectious Diseases.

Comparison of risk factors for SARS-CoV-2 infection among healthcare workers during Omicron and Delta dominance periods in Japan

N. Ohmagari, J. Takeuchi, Y. Li, 2023, Journal of Hospital Infection.

Evaluating the Immunogenicity and Safety of a Smallpox Vaccine to Monkeypox in Healthy Japanese Adults: A Single-Arm Study

M. Shimojima, H. Ebihara, N. Ohmagari, 2023, Life.

Sex‐associated differences between BMI and SARS‐CoV‐2 antibody titers following the BNT162b2 vaccine

K. Miyo, N. Ohmagari, H. Sugiyama, 2022, Obesity.

Durability and determinants of anti-SARS-CoV-2 spike antibodies following the second and third doses of mRNA COVID-19 vaccine

N. Ohmagari, S. Yamamoto, M. Konishi, 2022, medRxiv.

Effectiveness of remdesivir in hospitalized nonsevere patients with COVID-19 in Japan: A large observational study using the COVID-19 Registry Japan

N. Ohmagari, Y. Asai, S. Tsuzuki, 2022, International Journal of Infectious Diseases.

Pre-infection neutralizing antibodies, Omicron BA.5 breakthrough infection, and long COVID: a propensity score-matched analysis

S. Oka, N. Ohmagari, J. Takeuchi, 2023, medRxiv.

Protocol of an Exploratory Single-Arm Study to Evaluate the Safety and Immunogenicity of KD-414 as a Booster Vaccine for SARS-CoV-2 in Healthy Adults (KAPIVARA)

Y. Takamatsu, J. Takeuchi, Y. Uemura, 2022, Life.

Clinical characteristics of the first three waves of hospitalised patients with COVID-19 in Japan prior to the widespread use of vaccination: a nationwide observational study

H. Ohtsu, N. Ohmagari, Y. Asai, 2022, The Lancet Regional Health - Western Pacific.

Association between γ-Glutamyl Transpeptidase and SARS-CoV-2 Spike Antibody Titers among BNT162b2 Vaccine Recipients

N. Ohmagari, T. Mizoue, M. Konishi, 2022, Vaccines.

Children ’ s Non-isomorphic Interpretation in Japanese Conditionals

Hiroyuki Shimada, W. Sugiura, 2017 .

Switching from entecavir to tenofovir disoproxil fumarate for HBeAg-positive chronic hepatitis B patients: a phase 4, prospective study

M. Kudo, Y. Karino, T. Ide, 2021, BMC Gastroenterology.

SARS-CoV-2 specific T cell and humoral immune responses upon vaccination with BNT162b2: a 9 months longitudinal study

N. Ohmagari, J. Takeuchi, Y. Kito, 2022, Scientific Reports.

Correlates of Neutralizing/SARS-CoV-2-S1-binding Antibody Response with Adverse Effects and Immune Kinetics in BNT162b2-Vaccinated Individuals

S. Oka, Y. Takamatsu, Y. Uemura, 2021, medRxiv.

Immunogenicity and safety of single booster dose of KD-414 inactivated COVID-19 vaccine in adults: An open-label, single-center, non-randomized, controlled study in Japan

Y. Takamatsu, N. Ohmagari, J. Takeuchi, 2023, Human vaccines & immunotherapeutics.

Efficacy of convalescent plasma therapy for COVID-19 in Japan: An open-label, randomized, controlled trial

Akiko Kimura, M. Satake, Y. Takamatsu, 2023, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy.

Validation of the severe COVID-19 prognostic value of serum IL-6, IFN-λ3, CCL17, and calprotectin considering the timing of clinical need for prediction

N. Ohmagari, J. Takeuchi, K. Yamamoto, 2023, PloS one.

Dyslipidemia and SARS‐CoV‐2 spike antibody titres after the second and third doses of the BNT162b2 vaccine among healthcare workers in Japan

N. Ohmagari, T. Mizoue, M. Konishi, 2022, Diabetes/metabolism research and reviews.

An open-label, non-randomized study investigating the safety and efficacy of smallpox vaccine, LC16, as post-exposure prophylaxis for mpox

N. Ohmagari, Y. Uemura, M. Ujiie, 2023, Human vaccines & immunotherapeutics.

Association of demographics, HCV co‐infection, HIV‐1 subtypes and genetic clustering with late HIV diagnosis: a retrospective analysis from the Japanese Drug Resistance HIV‐1 Surveillance Network

S. Matsushita, M. Koga, T. Matano, 2023, Journal of the International AIDS Society.

Efficacy and Safety of the Smallpox Vaccine for Postexposure Prophylaxis in Monkeypox: Protocol for an Open-Labeled, Single-Armed Study

N. Ohmagari, Y. Uemura, M. Ujiie, 2023, JMIR research protocols.

Efficacy of convalescent plasma therapy for COVID-19 in Japan: An open-label, randomized, controlled trial

S. Kutsuna, N. Ohmagari, I. Hamaguchi, 2023 .

An Association Study of HLA with the Kinetics of SARS-CoV-2 Spike Specific IgG Antibody Responses to BNT162b2 mRNA Vaccine

K. Tokunaga, N. Ohmagari, J. Takeuchi, 2022, Vaccines.

Successful use of casirivimab/imdevimab anti-spike monoclonal antibodies to enhance neutralizing antibodies in a woman on anti-CD20 treatment with refractory COVID-19

Y. Takamatsu, N. Ohmagari, J. Takeuchi, 2022, Journal of Infection and Chemotherapy.